

depleting pro-B cells are not available presently. This proposed strategy could be tested in the experimental models we have described before any clinical application. As such, these mutant mouse strains provide valuable models to test new approaches to improve the current results of HSCT for inherited primary immunodeficiencies such as SCID.

References

- Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A. Gene therapy for severe combined immunodeficiency. *Annu Rev Med.* 2005; 56:585-602.
- Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. *Immunol Rev.* 2005;203:127-142.
- Giliani S, Mori L, de Saint Basile G, et al. Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases: analysis of clinical, immunological, and molecular features in 16 novel patients. *Immunol Rev.* 2005;203:110-126.
- Gougeon ML, Dreon G, Le Deist F, et al. Human severe combined immunodeficiency disease: phenotypic and functional characteristics of peripheral B lymphocytes. *J Immunol.* 1990;145:2873-2879.
- Johnson SE, Shah N, Panoskaltis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. *J Immunol.* 2005;175:7325-7331.
- Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency: a model disease for molecular immunology and therapy. *Immunol Rev.* 2005;203:98-109.
- Agematsu K, Nagumo H, Hokibara S, et al. Complete arrest from pro- to pre-B cells in a case of B cell-negative severe combined immunodeficiency (SCID) without recombination activating gene (RAG) mutations. *Clin Exp Immunol.* 2001; 124:461-464.
- Noordzij JG, Verkaik NS, van der Burg M, et al. Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. *Blood.* 2003;101:1446-1452.
- Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. *Lancet.* 2003;361:553-560.
- Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. *Blood.* 1998;91:3646-3653.
- Tjonnfjord GE, Steen R, Veiby OP, Friedrich W, Egeland T. Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID. *Blood.* 1994; 84:3584-3589.
- Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. *N Engl J Med.* 1999;340:508-516.
- Haddad E, Le Deist F, Aucouturier P, et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-center study of 22 patients. *Blood.* 1999; 94:2923-2930.
- Vosshenrich CA, Cumano A, Muller W, Di Santo JP, Vieira P. Thymic stromal-derived lymphopoietin distinguishes fetal from adult B cell development. *Nat Immunol.* 2003;4:773-779.
- Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. *Cell.* 1992; 68:855-867.
- DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. *Proc Natl Acad Sci U S A.* 1995; 92:377-381.
- Hardy RR, Hayakawa K. B cell development pathways. *Annu Rev Immunol.* 2001;19:595-621.
- Allman D, Srivastava B, Lindsley RC. Alternative routes to maturity: branch points and pathways for generating follicular and marginal zone B cells. *Immunol Rev.* 2004;197:147-160.
- Vosshenrich CA, Ranson T, Samson SI, et al. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. *J Immunol.* 2005;174:1213-1221.
- Zeigler FC, Bennett BD, Jordan CT, et al. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. *Blood.* 1994;84:2422-2430.
- Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. *Immunity.* 1995;3:147-161.
- Puck JM, Nussbaum RL, Conley ME. Carrier detection in X-linked severe combined immunodeficiency based on patterns of X chromosome inactivation. *J Clin Invest.* 1987;79:1395-1400.
- Le Deist F, Poinson C, Moshous D, Fischer A, de Villartay JP. Artemis sheds new light on V(D)J recombination. *Immunol Rev.* 2004;200:142-155.
- Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. *Lancet.* 1990;336:850-854.
- Malek SN, Flinn IW. Incorporating monoclonal antibodies in blood and marrow transplantation. *Semin Oncol.* 2003;30:520-530.
- Rieux-Laucat F, Hivroz C, Lim A, et al. Inherited and somatic CD3Z mutations in a patient with T-cell deficiency. *N Engl J Med.* 2006;354:1913-1921.

Erratum

In the article by Pellagatti et al entitled "Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype," which appeared in the July 1, 2006, issue of *Blood* (Volume 108:337-345), in "Materials and methods" in the last sentence of "Data analysis" the incorrect GEO series accession number was published. The correct GEO series accession number is GSE4619.